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Abstract: Resveratrol is a potent member of the class of natural, plant-derived chemicals known 
as polyphenols. These help explain in part why a diet high in fruit and vegetables confers health 
beneﬁ  ts and are associated with reduced risk of common complex conditions such as cardiovas-
cular disease, cancer, diabetes, and Alzheimer’s disease. We present the latest molecular ﬁ  ndings 
that account for the beneﬁ  cial actions of resveratrol. The intracellular pathways activated are 
crucial for anti-oxidant defence, regulation of the cell cycle, mitochondrial energy production, 
vascular tone, oncogene suppression, and many other phenomena which if unchecked lead to 
morbidity and mortality from onset and progression of these various diseases. While a healthy 
diet and lifestyle is strongly recommended in prevention of such conditions, the future bodes 
well for the use of resveratrol and analogues of higher potency than the natural form for treat-
ment of diseases that afﬂ  ict humans, particularly as they age.
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Introduction
Resveratrol (trans-3,5,4'-trihydroxystilbene or 5-[(E)-2-(4-hydroxyphenyl)-
ethenyl]benzene-1,3-diol; C14H12O3) (Figure 1), is a polyphenolic ﬂ  avonoid found in 
the seeds and skins of grapes, red wine, mulberries, peanuts, and rhubarb. Polyphenols 
exert a diversity of health beneﬁ  ts by activating intracellular pathways, many of which 
are the same as those activated by calorie restriction, an intervention long known to 
enhance health and prolong lifespan (Wood et al 2004). An early target of resveratrol 
is the sirtuin class of nicotinamide adenine dinucleotide (NAD)-dependent deacety-
lases. Seven sirtuins have been identiﬁ  ed in mammals, of which SIRT-1 is believed 
to mediate the beneﬁ  cial effects on health and longevity of both calorie restriction 
and resveratrol (Guarente and Picard 2005). A number of intracellular pathways are 
activated by SIRT-1 (Figure 2). The extent to which the sirtuin-activating actions of 
resveratrol are direct or indirect is still not resolved completely (Denu 2005). The 
pathways regulated by sirtuins include gluconeogenesis and glycolysis in the liver, 
fat metabolism, and cell survival. Depending on cell type and circumstances, sirtuins 
activate or suppress members of the forkhead box O (FOXO) group of transcription 
factors. FOXOs then activate or suppress speciﬁ  c genes, leading to a decrease in 
apoptosis, an increase in antioxidant activities, DNA protection, anti-inﬂ  ammatory 
effects, and modulation of various other mechanisms so as to promote the health 
of the cell, and thus the organism (reviewed by Morris 2005, 2008). It may be that 
sirtuins beneﬁ  t survival by ramping up stress resistance pathways in cells in times of 
adversity (Guarente and Picard 2005). Several recent reports presented evidence that 
SIRT-1 interacts directly and deacetylates the metabolic regulator and transcriptional 
coactivator, peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α). 
By doing so it improves mitochondrial function, induces genes for mitochondrial and Clinical Interventions in Aging 2008:3(2) 332
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fatty acid oxidation and increases mitochondrial membrane 
potential (Lagouge et al 2006; Gerhart-Hines et al 2007; 
Anderson et al 2008).
A recent study deﬁ  ned class IA phosphoinositide 3-
kinase (PI3K) as another direct target of resveratrol thus 
conﬁ  rming earlier ﬁ  ndings of involvement of resveratrol in 
the PI3K pathway (Frojdo et al 2007). This could represent a 
sirtuin-independent pathway central to the control of lifespan 
implicating insulin-like signalling through the P13K/protein 
kinase B cascade and the downstream FOXOs.
The ability of resveratrol to mimic the beneﬁ  cial effects 
that calorie restriction has on the lifespan of Saccharomyces 
cerevisiae was ﬁ  rst noted by David Sinclair and co-workers 
(Howitz et al 2003). Since then the effect of resveratrol on 
a number of other organisms such as Drosophila melano-
gaster, Caenorhabditis elegans, and Nothobranchius furzeri 
has been tested, and in each case an increase in mean lifes-
pan of between 18% and 56% was seen (Wood et al 2004; 
Valenzano et al 2006). In the fruit ﬂ  y and the nematode, the 
effect that resveratrol had on lifespan was dependent on Sir2 
and SIR-2.1, the respective homologues of the mammalian 
protein, SIRT-1. Some reports have challenged these ﬁ  nd-
ings. Kaeberlein and co-workers (2005), for instance, were 
unable to reproduce the results in two different strains of 
yeast, instead showing that resveratrol did not signiﬁ  cantly 
increase the lifespan of the cells. Likewise, another study 
found that resveratrol is not a general activator of Sir2 and 
that activation requires the presence of a covalently bound 
ﬂ  uorophore (Borra et al 2005). In the same year Guarente’s 
group found that resveratrol inhibits, rather than activates, 
SIR-2.1 in C. elegans, questioning the dogma that the wide 
effects of resveratrol are always a result of sirtuin activa-
tion. The involvement of the sirtuins in lifespan extension 
remains quite controversial. While some researchers have 
Figure 1 Chemical structure of resveratrol.
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Figure 2 SIRT-1 activation pathways. Resveratrol and calorie restriction activate similar SIRT-1–mediated pathways whose actions result in prevention of common age-related 
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found that caloric restriction-mediated increases in longevity 
are sirtuin-dependent in yeast (Lin et al 2000), Drosophila 
(Rogina and Helfand 2004) and nematode (Wang and 
Tissenbaum 2006), others have found that sirtuins are not 
required (Kaeberlein et al 2004; Smith et al 2007). Further-
more, overexpression of any of the human sirtuins could not 
extend the lifespan of normal human ﬁ  broblasts or prostate 
epithelial cells (Michishita et al 2005). As well, resveratrol 
was not able to extend the replicative lifespan of human 
ﬁ  broblasts in culture (Stefani et al 2007).
On the other hand, we have found that resveratrol sup-
pressed expression of mRNA for the senescence-inducer 
INK4, and by microarray analysis found that resveratol 
modulated expression of a number of genes such as those 
involved in the Ras pathway, apoptosis, cell growth, and 
division, G-protein signalling, cell – cell adhesids, immune 
system regulation, neuroendocrine signalling, muscle devel-
opment, transcription, and proteolysis; ie, were mostly ones 
expected to affect cell lifespan (Stefani et al 2007).
In 2006, the effect of resveratrol on lifespan of mam-
mals, namely a mouse model of obesity, was reported by 
two groups: Sinclair’s and that of Johan Auwerx (Baur et al 
2006; Lagouge et al 2006). The ﬁ  ndings have provoked, 
yet again, the perennial question: ‘Can resveratrol improve 
human health and lifespan?’
The present review will discuss the recent resveratrol 
studies in mice, their relevance to longevity, and the ability to 
cure age-related diseases. Some new ﬁ  ndings on resveratrol’s 
protection against cardiovascular disease, cancer, and neu-
rological disorders will also be discussed.
Effects on metabolism, 
performance, and survival
Resveratrol is metabolized rapidly, and for this reason the 
question has often been posed as to whether resveratrol 
has any effect in mammals in vivo. The two studies in 
2006, by Sinclair’s laboratory at Harvard, reported in 
Nature, and by Auwerx group in France, published in 
Cell, produced tantalizing ﬁ  ndings in mice that support 
powerful actions of resveratrol in mammals. Each research 
team tested three groups of mice: one on a normal diet, 
one on a high calorie diet, and the third on a high calorie 
plus resveratrol regimen. The Sinclair study used a lower 
dose given in ‘middle age.’ The Auwerx study used a dose 
more than ten-fold higher and that was given from an early 
age. While some differences were seen, by and large the 
effects resveratrol elicited in the mice in each laboratory 
were astonishingly similar.
Sinclair’s group showed that resveratrol could prevent 
most of the ill effects of the high-fat diet by shifting many 
physiological parameters of mice on a calorie-rich diet 
towards those of mice on a standard diet, and thereby reduc-
ing the risk of diabetes, fatty liver, cardiovascular disease, 
and cancer (Baur et al 2006). As a result the mice lived 30% 
longer, ie, had the same lifespan as the mice on a normal diet, 
even though the mice stayed fat and had high cholesterol 
(Baur et al 2006). One unanswered question in this study 
was whether mice on a normal diet could also have their 
lifespan extended by resveratrol. In the Harvard study, the 
plasma levels of resveratrol achieved in the mice on a normal 
diet were lower than those in the obese mice. Therefore, to 
test the effect in mice on a normal diet, the experiment had 
to be repeated by giving the mice a diet containing higher 
resveratrol so as to achieve similar plasma levels as was seen 
in the mice on a high calorie diet. The mice lived slightly 
longer, but this did not reach statistical signiﬁ  cance (D.A. 
Sinclair, personal communication).
Shortly after Sinclair’s 2006 study was published, 
Auwerx’s group reported that resveratrol, given at up to 
20-fold higher dose to younger (1–2 month old) mice, could 
prevent diet-induced obesity and enhance the aerobic capac-
ity of the mice (Lagouge et al 2006). Resistance to muscle 
fatigue was greatly improved in these mice, so that they could 
run twice as far before exhaustion (Lagouge et al 2006). 
This particular ﬁ  nding has attracted widespread interest in 
all ﬁ  elds relevant to human physical performance, ranging 
from athletic sports to active military service.
Both the Sinclair and Auwerx groups found that in 
resveratrol-treated mice insulin sensitivity and motor function 
were improved, and mitochondrial activity was increased sig-
niﬁ  cantly (Baur et al 2006; Lagouge et al 2006). The latter ties 
in nicely with results both groups obtained from measuring 
the activity of PGC-1α. They found that in resveratrol-treated 
mice the acetylation status of PGC-1α was greatly decreased, 
and thus its activity was increased enormously (Baur et al 
2006; Lagouge et al 2006). This is an important result, because 
mitochondrial biogenesis in liver and muscle is by and large 
controlled by PGC-1α, deacetylation of which is positively 
regulated by SIRT-1 (Lin et al 2002; Gerhart-Hines et al 
2007; Anderson et al 2008). Thus resveratrol, via stimulation 
of the SIRT-1-mediated deacetylation of PGC-1, improves 
mitochondrial function and energy balance in mice (Baur 
et al 2006; Lagouge et al 2006) (Figure 2). In muscle, this 
leads to an increase in oxidative-type muscle ﬁ  bres. As part 
of this action, the two studies found that genes relevant to the 
changes seen in liver (Baur et al 2006) and skeletal muscle Clinical Interventions in Aging 2008:3(2) 334
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(Lagouge et al 2006) were induced, as identiﬁ  ed by whole 
genome expression proﬁ  ling. In the French study, skeletal 
muscle from resveratrol-treated mice showed the greatest 
increases in expression for genes involved in processes such 
as ribosomal mRNA processing, striated muscle contraction, 
the electron transport chain, oxidative phosphorylation and 
adenosine 5'-triphosphate (ATP) synthesis (Lagouge et al 
2006), supporting the notion that resveratrol affected mito-
chondrial biogenesis and enhanced oxidative capacity of the 
muscle. The US study, which tested liver samples, found that 
the most signiﬁ  cant alterations were in gene sets affecting 
the tricarboxylic acid (TCA) cycle, glycolosis, complement 
pathways, butanoate and propanoate metabolism, Stat3 signal-
ling, as well as insulin signaling, insulin-like growth factor-1 
and mTPR signaling, oxidative phosphorylation, and electron 
transport (Baur et al 2006). Notably, Cidea, which regulates 
energy balance in brown fat and protects against obesity 
and diabetes, when knocked out, was shown to be the gene 
whose expression was most highly upregulated in the high-fat 
mice and second most highly downregulated in the high-
fat-resveratrol group. These results highlight the similarities 
between resveratrol- and calorie restriction-induced pathways, 
and at the same time underline the observation that resvera-
trol-induced effects are tissue-speciﬁ  c.
The differences between each study might have arisen 
from differences in design aspects. In the Auwerx study, the 
mice were young and were fed resveratrol for three months, 
and, as a result of this, they gained nearly complete protec-
tion from high fat diet-induced obesity (Lagouge et al 2006). 
In the Sinclair study, the mice fed resveratrol were older 
(1 year), the dose was over ten times lower (5–22 versus 
200–400 mg/kg body weight/day) and they were given 
resveratrol for a year in order to see whether this would 
improve their insulin sensitivity and lifespan when put on 
a high fat diet (Baur et al 2006). Despite improved hepatic 
glucose and lipid metabolism, the mice were not protected 
from obesity. They did not, however, develop hepatic steosis 
(fatty liver), diabetes, cardiovascular disease, or cancer, each 
of which were seen in the high-fat fed controls. No change 
in liver histology was observed in the French study, but 
this could have been contributed by their younger age and 
the much shorter treatment with resveratrol that they were 
subjected to.
Despite the increase in deacetylated PGC-1α in liver, an 
effect that would normally increase gluconeogenesis, lower 
glucose levels were noted. This was explained by activa-
tion of adenosine monophosphate (AMP)-activated protein 
kinase (AMPK), which potently inhibits gluconeogenesis. 
AMPK would also protect from fatty liver, since it increases 
fatty acid oxidation by inhibiting the rate-limiting enzyme in 
fatty acid synthesis, acetyl coA carboxylase. This outcome 
comﬁ  rms earlier ﬁ  ndings that polyphenols stimulate AMPK 
and lower plasma lipid concentration in diabetic low-den-
sity lipoprotein (LDL) receptor-deﬁ  cient mice (Zang et al 
2006). The ﬁ  ndings support a parallel between the SIRT-1 
and AMPK signaling pathways (Koo and Montminy 2006). 
Both are triggered by fasting, and are energy-sensing in 
that they respond to changes in NAD+ and AMP. Each can 
increase lifespan and enhance glucose utilization as well 
as insulin sensitivity. Each pathway converges on PGC-1α 
and most certainly other regulators of glucose and lipid 
metabolism.
A reduction in core body temperature is associated 
with reduced energy expenditure and improved survival in 
mice, and vice versa (Conti et al 2006), yet the increased fat 
metabolism by the mitochondria-rich brown fat, leading to 
more adipose tissue burn off, suggests that the higher dose 
of resveratrol used in the Auwerx study was sufﬁ  cient to 
trigger SIRT-1 activation (Koo and Montminy 2006). The 
10–20-fold lower doses of resveratrol in the study by the Sin-
clair group could possibly explain why core body temperature 
did not increase in their mice and why their mice were not 
protected from obesity (Koo and Montminy 2006).
In humans, the possibility of a direct involvement of 
SIRT-1 in energy expenditure, was suggested by a case-
control study carried out by Auwerx and co-workers. This 
showed that nondiabetic offspring of Finnish diabetic patients 
were more likely to show an association of particular alleles 
of three single nucleotide polymorphisms of SIRT-1 with 
energy expenditure (Lagouge et al 2006). They proposed 
that this could partially explain why different people respond 
differently to a high-fat diet. The ﬁ  nding might thus be 
relevant to the mechanisms responsible for obesity and/or 
diabetes, as well as other conditions. It should, however, be 
noted that genetic studies are notoriously unreproducible in 
different settings, so that much more research is needed to 
conﬁ  rm the veracity of this particular genetic association 
before it can be generally accepted.
Cardiovascular protection
Moderate consumption of red wine is often associated with 
a lower incidence of cardiovascular diseases in popula-
tions with a high fat diet, a notion that has been termed 
the ‘French Paradox’ (Renaud and de Lorgeril 1992). 
Since resveratrol has been found to be a component in red 
wine it has often been used to explain the French Paradox. Clinical Interventions in Aging 2008:3(2) 335
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The amount of red wine that a person needs to consume 
in order to acquire an equivalent amount of resveratrol to 
the amount used in the Sinclair experiments (Baur et al 
2006) has, however, been estimated as approx. 52 bottles 
per day! Therefore, resveratrol in red wine is unlikely to 
explain the ‘French Paradox’, despite the possibility of 
positive effects of red wine on the cardiovascular system; 
discussed later (Lefevre et al 2007).
The inhibitory effects of resveratrol on cardiovascular 
disease may be similar to those of 25% calorie restriction 
over 6 years in humans (Fontana et al 2004). These effects 
include a reduction in platelet aggregation, dilatation of 
blood vessels, antiatherosclerotic effects, lowering of lipid 
peroxidation, reduction in endothelin-1, protection of endo-
thelial cells against apoptosis, lowering of blood pressure, 
oxidative stress and end-organ damage in hypertensive ani-
mals, as well as improvement of serum cholesterol proﬁ  le 
and triglyceride concentrations. These effects have all been 
carefully reviewed (Baur and Sinclair 2006; Perez-Vizcaino 
et al 2006; Morris 2007, 2008).
One explanation for the cardioprotective effect of 
resveratrol is its ability to prevent platelet aggregation 
through selective inactivation of the prostaglandin H2 
synthase, cyclooxygenase (Cox)-1, over Cox-2 (Szewczuk 
et al 2004), in much the same way as aspirin. Resveratrol 
is also a powerful inhibitor of the peroxidase reactions of 
Cox-1. Its weak inhibition of Cox-2, the isoform targeted 
by nonsteroidal anti-inﬂ  ammatory drugs, is, moreover, 
confined to cyclooxygenase activity (Szewczuk et al 
2004). Cox-1 synthesizes thromboxane A2, which is a 
strong inducer of platelet aggregation and vasoconstric-
tion, whereas inhibition of Cox-2 can increase thrombus 
formation (Mukherjee et al 2001). In a recent in vivo study, 
resveratrol (5 mg/kg) signiﬁ  cantly prolonged platelet plug 
formation of mice (Shen et al 2007). This study suggested 
that the inhibitory effect of resveratrol involves inhibition 
of the p38 mitogen activated protein kinase (MAPK), cyto-
solic phospholipase A2 (cPLA2), arachidonic acid (AA), 
thromboxane A2 (TxA2), intracellular calcium concentration 
[Ca2+]i cascade, and activation of nitric oxide (NO)/cyclic 
guanosine monophosphate (GMP), resulting in inhibition 
of phospholipase C (PLC) and/or protein kinase C (PKC) 
activation, thereby leading to inhibition of [Ca2+]i or free 
radical formation, and ﬁ  nally inhibition of platelet aggrega-
tion (Shen et al 2007).
The vasodilator effect of resveratrol involves inhibition of 
TxA2 formation and the ability of resveratrol to stimulate Ca2+-
activated K+ channels (Li et al 2000), as well as NO signaling 
in the endothelium by inhibiting vascular NADH/NADPH 
oxidase activity. This then results in suppression of super-
oxide production and thus reduces NO inactivation (Orallo 
et al 2002). Resveratrol, but not other ﬂ  avonoids, can induce 
expression of endothelial NO synthase (eNOS) and inducible 
NO synthase (iNOS) (Leikert et al 2002; Wallerath et al 2002; 
Das et al 2005; Leighton et al 2006). It also affects L-citrulline 
production by vascular endothelial cells (Leikert et al 2002). 
The increase in eNOS in blood vessel walls in response to red 
wine polyphenols, particularly resveratrol, contributes to vaso-
dilatation by enhancing NO production (Räthel et al 2007). 
This was delineated recently in a paper that showed moderate 
consumption of red wine in mice improves ischemia-induced 
neovascularization in high-cholesterol conditions by restoring 
the Akt (protein kinase B) – eNOS – NO pathway and by 
increasing the number and function of endothelial progenitor 
cells (Lefevre et al 2007).
Another possible mechanism by which resveratrol exerts its 
beneﬁ  cial effect on the cardiovascular system is through its anti-
oxidant activity. An association has been found between oxida-
tion of LDL particles and risk of heart disease and myocardial 
infarction. Resveratrol prevents oxidation of LDL by chelating 
copper and by scavenging reactive oxygen species (ROS) (Fran-
kel et al 1993). The fact that resveratrol can be detected in LDL 
particles after red wine consumption by humans (Urpi-Sarda 
et al 2005) is consistent with its ability to prevent peroxidation 
of lipids and other macromolecules (Baur and Sinclair 2006). 
Furthermore, resveratrol activates the cholesterol efﬂ  ux genes 
ATP-binding cassette transporter 1 (ABCA1) and ATP-binding 
cassette transporter G1 (ABCG1), as well as transcription fac-
tors that inﬂ  uence the nuclear liver receptor-α (LXR-α) gene, 
resulting in a more limited cholesterol accumulation by human 
macrophages. Resveratrol also represses the expression of the 
lipid uptake genes lipoprotein lipase and scavenger receptor 
AII (SR-AII) (Sevov et al 2006).
Multiple and complex pathways are therefore involved in 
the beneﬁ  cial effects of resveratrol and other polyphenols on 
cardiovascular health. Their various effects protect against 
hypertension, ischemic heart disease, ischemic damage 
during myocardial infarction, and brain damage following 
cerebral ischemia, so explaining the inverse association that 
has been seen between dietary ﬂ  avonoid consumption and 
cardiovascular mortality (Baur and Sinclair 2006; Perez-
Vizcaino et al 2006).
Cancer
The ﬁ  rst-observed, and now well-established, effect of res-
veratrol is its potential to inhibit the initiation and growth Clinical Interventions in Aging 2008:3(2) 336
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of tumors in a range of cancer models of both mouse and 
rat. Amongst many other such effects, resveratrol has been 
shown to prevent colon cancer (Tessitore et al 2000) and 
prostate cancer (Harper et al 2007), and to substantially 
increase survival of mice with subcutaneous neuroblastomas 
(Chen et al 2004). Its effect on breast cancer is controver-
sial, where resveratrol either failed to have any positive 
effect (Bove et al 2002) or prevented cancer progression in 
vivo (Whitsett et al 2006; Su et al 2007). Resveratrol was, 
moreover, found to inhibit angiogenesis in human xenografts 
(Garvin et al 2006).
The multiple, and perhaps cumulative, mechanisms by 
which resveratrol slows tumour development have been 
reviewed thoroughly by Baur and Sinclair (2006). These 
include inhibition of angiogenesis, alterations in cell cycle 
and apoptosis, as well as antioxidant effects. Some of 
these mechanisms seem to be due to the suppression by 
resveratrol of cyclooxygenases and ornithine decarbox-
ylase expression, both enzymes that normally promote 
angiogenesis (Baur and Sinclair 2006). It has been reported 
that resveratrol also inhibits cytochrome P450s, which are 
enzymes involved in drug metabolism and that are con-
sidered pro-carcinogens (Ciolino et al 1998; Zhou et al 
2005). This was strengthened by ﬁ  ndings in the microarray 
analyses of livers from resveratrol-treated mice, in which 
downregulation of three cytochrome P450 enzymes was 
observed (Baur et al 2006).
Another possible mechanism for the protective effect 
of resveratrol against cancer relates to its antiproliferative 
and proapoptotic effects (Aggarwal et al 2004), leading to 
downregulation of cell cycle proteins and an increase in apop-
tosis of tumor cells (reviewed in Baur and Sinclair 2006). 
While these effects have been seen in vitro, the study of 
obese mice by Sinclair’s group (Baur et al 2006) produced 
somewhat conflicting results. When they compared a 
parametric analysis of gene set enrichment (PAGE) from 
resveratrol-treated fat mice with a preexisting caloric 
restriction data set known as AGEMAP, they found that 
cell cycle checkpoint and apoptotic pathways were elevated 
in the caloric restriction group, but downregulated in the 
resveratrol-treated group. Hepatic apoptosis was, however, 
unchanged, and the authors suggested that downregulation 
of the cell cycle checkpoints may be linked to the recent 
ﬁ  nding that inhibition of checkpoint function increases stress 
resistance and lifespan in C. elegans (Olsen et al 2006).
The antioxidant effects of resveratrol could contribute 
to its anticancer properties. This is because ROS, by dam-
aging DNA and other macromolecules, can contribute to 
the initiation and progression of cancer (Baur and Sinclair 
2006). It is not clear whether these are direct effects or a 
consequence of the upregulation of antioxidant enzymes 
by resveratrol.
It will be interesting to learn the results of several phase 
I clinical trials that are currently being conducted and which 
involve oral administration of resveratrol to humans in the 
USA and the UK (Baur and Sinclair 2006).
Neurological disorders
The underlying pathogenic processes of neurodegenerative 
disorders are similar and are linked to pathways that are 
important during the aging process. It is thus not surprising 
that resveratrol has been shown to confer neuronal protec-
tion in in vitro studies (reviewed by Anekonda 2006). Chen 
and co-workers (2005) showed that by activating SIRT-1, 
resveratrol inhibited, indirectly, nuclear factor κB (NF-κB) 
signalling and thus protected against microglia-dependent 
β-amyloid toxicity in a model of Alzheimer’s disease. 
This progressive age-related, neurodegenerative disorder 
is characterized by the presence of neuroﬁ  brillary tangles 
and extracellular amyloid β plaques in the cortex and hip-
pocampus, areas of the brain that are important for memory 
and learning. A recent study by Kim and associates (2007) 
has now provided the in vivo evidence in two mouse models 
of neurodegenerative diseases, namely Alzheimer’s disease 
and amyotrophic lateral sclerosis (ALS). They found that 
resveratrol reduced signiﬁ  cantly the extent of neuronal cell 
death and neurotoxicity of the mutant proteins expressed in 
these two models (p25, a toxic coactivator of CDK5, and 
a mutant form of superoxide dismutase 1, respectively). 
Administration of resveratrol reduced neurodegeneration 
in the hippocampus and rescued associative learning in 
p25 mice (Kim et al 2007). Most importantly, the effect 
of resveratrol was mediated by SIRT-1, via increased 
deacetylation of p53 and/or PGC-1α, conﬁ  rming earlier 
ﬁ  ndings of the role of PGC-1α in neuronal metabolism 
(St-Pierre et al 2006) and the link between resveratrol, 
SIRT-1, and PGC-1α discussed above. By repressing p53, 
resveratrol may protect neurons from oxidative damage 
and prevent apoptotic neuronal death. Another possible 
pathway involved in promoting neuronal survival involves 
suppression or activation of FOXO proteins. This has been 
supported by work in Huntington’s disease models of both 
mice and C. elegans, where resveratrol rescued early neu-
ronal dysfunction phenotypes induced by mutant polygluta-
mines. In the nematode this effect was dependent on daf-16, 
a member of the FOXO family (Parker et al 2005).Clinical Interventions in Aging 2008:3(2) 337
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There is evidence that Alzheimer’s disease is caused by 
the accumulation of localized neuronal damage surrounding 
hemorrhagic mini-strokes in the vicinity (Cullen et al 2006). 
Thus, the general cardiovascular protection provided by 
resveratrol in the brain is another way in which it may be 
protecting against this disease. In addition numerous studies 
have shown that brain damage caused by ischemia, stroke, 
seizure, and epilepsy is reduced markedly after treatment 
with resveratrol (Anekonda 2006).
Resveratrol thus offers promise for the treatment and 
prevention of Alzheimer’s disease, but also Parkinson’s dis-
ease, Huntington’s disease, and other neurological disorders 
(Anekonda 2006).
Dose and metabolism
The wide range of resveratrol doses used in animal studies 
(0.1 to 1.500 mg/kg body weight) (Baur and Sinclair 2006), 
as well as the fact that resveratrol is absorbed and metabolized 
rapidly after oral ingestion by humans (Walle et al 2004), 
makes it difﬁ  cult to estimate a dose to be recommended 
as a therapeutic supplement or treatment. Since it is the 
metabolites of resveratrol, rather than free resveratrol, that 
tend to be detected in the urine up to 9 hours after ingestion, 
it has often been suggested that it is these metabolites that 
retain or mediate at least some of the beneﬁ  cial effects (Baur 
and Sinclair 2006). The levels of resveratrol and its deriva-
tives attained after ingestion of 25 mg in a 70 kg adult are 
approximately 20–40 nmol/L and 2000 nmol/L, respectively 
(Yu et al 2002).
The potency of polyphenol extracts from different grape 
vine cultivars varies considerably (Räthel et al 2007). Baur 
and Sinclair (2006) optimistically estimate that at a concen-
tration of 5 mg/l in red wine, two glasses (375 ml) would 
equal a dose of 27 µg/kg in a 70 kg person. This would result 
in peak serum concentrations of approximately 2.4 nM of 
free resveratrol and 180 nM of modiﬁ  ed resveratrol. A recent 
Spanish study estimated that the total resveratrol intake for 
men and women is on average 1629 µg/day and 235 µg/day, 
respectively (Zamora-Ros et al 2007). A pharmacologi-
cally relevant dose, however, would have to be more like 
100 mg/kg body weight or about 9 µM free resveratrol and 
680 µM total resveratrol (Baur and Sinclair 2006). Such doses 
have so far shown no adverse side effects in animal models 
(Crowell et al 2004; Lagouge et al 2006). Many supplement 
companies offer resveratrol for purchase on the internet, but, 
since these are not regulated, the consumer should be more 
than cautious about buying them. Purity, origin, and age of 
the product are often unknown. Many of the preparations 
available on the market can, moreover, exhibit substantial 
depletion of activity by the time they reach the consumer. 
Products are offered at costs of about $US1 per 300 mg of 
resveratrol per capsule, which, at an intake of one capsule 
per day, would amount to monthly costs of US$30. However, 
300 mg of resveratrol would probably have less effect than 
the amount of resveratrol present in a daily glass of red wine, 
so to achieve the various substantive results discussed in the 
present review, the cost of 100 mg/kg body weight needs to 
be considered. This would amount to approximately $US600 
a month for an average person of 70 kg (Baur and Sinclair 
2006). The development of more stable analogues and the 
outcomes of clinical trials may progress both efﬁ  cacy and 
price-performance ratio of resveratrol.
What is more, since no long-term effects in mammals 
have been established, and given the large number of targets 
which have been found for resveratrol to date, it has to be 
emphasized that we are a long way from knowing whether 
this polyphenol is safe as a therapeutic or as a supplementary 
drug. The potential side-effects of resveratrol, especially from 
long-term consumption, have not been established in mam-
malian studies to date, and are a mystery in humans.
Lastly, it should be noted that resveratrol can be accumu-
lated in speciﬁ  c tissues (Vitrac et al 2003) and that it may act 
in synergy with other dietary compounds such as quercetin, 
ethanol, vitamin E, and catechin (Wallerath et al 2005; Baur 
and Sinclair 2006).
Effects of other phytochemicals
While a detailed discussion of other naturally-occurring 
polyphenols would go beyond the scope of this review, it 
should be stressed that many phytochemicals have been 
implicated in the prevention and treatment of common 
human diseases. Some of these include curcumin (from 
the roots of turmeric), epigallocatechin (from green tea), 
sulforaphane (found in broccoli), and quercetin. Similar 
to resveratrol, most of these phytochemicals have neuro-
protective, cancer-preventive, and positive cardiovascular 
effects. The major mechanism by which these agents 
were traditionally thought to exert their effects was by 
their antioxidative properties. In recent years, how-
ever, it has become clear that there are multiple cellular 
stress-response pathways and mechanisms activated in 
response to the polyphenols listed above. These include 
suppression of cytochrome P450 enzymes, induction of 
apoptotic pathways, suppression of cell cycle progression, 
chromatin remodelling, inhibition of angiogenesis, and 
anti-inﬂ  ammatory activity (for detailed reviews refer to Clinical Interventions in Aging 2008:3(2) 338
Markus and Morris
Dashwood et al 2006; Mattson and Cheng 2006; Myzak 
and Dashwood 2006; Juge et al 2007).
Conclusion
The biologically-potent polyphenol resveratrol has wide-
ranging effects on diverse biological processes in cells. 
Stimulation of these show enormous promise in the preven-
tion of common ills in our society. While we are eagerly 
awaiting the results of clinical trials, more research is required 
to fully understand the mechanisms whereby resveratrol 
exerts its effects and to exclude any potential long-term 
adverse side-effects.
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